Significant Options Trading on Wednesday: ADMA, RXO, DOCN
RXO Inc Options Trading: RXO Inc (Symbol: RXO) experienced options trading volume of 10,483 contracts, with significant activity in the $17.50 strike put option expiring February 20, 2026, accounting for 61.9% of its average daily trading volume.
DigitalOcean Holdings Inc Options Trading: DigitalOcean Holdings Inc (Symbol: DOCN) saw a trading volume of 17,847 contracts, particularly in the $50 strike call option expiring November 21, 2025, representing 61.4% of its average daily trading volume.
Comparison of Trading Volumes: The options trading volumes for both RXO and DOCN indicate a strong interest in specific strike prices, highlighting investor sentiment and potential market movements.
Resource for Options Information: For more details on available expirations for RXO, DOCN, and other options, StockOptionsChannel.com is recommended as a resource.
Trade with 70% Backtested Accuracy
Analyst Views on ADMA
About ADMA
About the author

ADMA Biologics CEO to Present at J.P. Morgan Healthcare Conference
- Conference Participation: ADMA Biologics CEO Adam Grossman will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 AM PT, showcasing the company's latest advancements in biopharmaceuticals, which is expected to attract investor interest.
- Product Portfolio: ADMA currently markets three FDA-approved plasma-derived biologics for treating immune deficiencies and preventing certain infectious diseases, highlighting the company's market positioning and expertise in niche medical areas.
- R&D Initiatives: ADMA is developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia, indicating the company's ongoing commitment to innovative drug development aimed at meeting the needs of specific patient populations.
- Manufacturing Capabilities: ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, ensuring the quality and stability of its biologics supply, thereby reinforcing its competitive advantage in the biopharmaceutical market.

Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
- Full Exit: Stonepine Capital sold all 38,597 shares of ANI Pharmaceuticals in Q3, valued at approximately $2.52 million, marking a complete exit from the company as of September 30.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has risen 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase during the same period, indicating strong market competitiveness.
- Financial Growth: ANI Pharmaceuticals reported a 54% year-over-year revenue surge to $227.8 million in the latest quarter, with adjusted EBITDA jumping nearly 70% to $59.6 million, prompting management to raise full-year revenue guidance to $873 million.
- Investment Strategy Shift: The exit by Stonepine does not reflect a lack of confidence in ANI but rather a capital rotation, indicating a preference for earlier-stage biotech investments, which suggests a cautious outlook on ANI's future growth potential.






